Clinical trials: in Mauritius
Human Immunodeficiency Virus Infections
Safety, PK and PD Study of ABX464 in Untreated HIV Patients
ABX464 is a first in class that showed efficacy as an anti-HIV therapy. The present study is intended to assess the safety, the tolerability, and pharmacokinetic parameters and to evaluate the effect on viral load of repeated…
- Trial name
- NCT02452242
- Testing
- ABX464
- Where
- 4 sites in Mauritius, Thailand
- Volunteers
- 70 people
- Sponsor
- Abivax S.A.
Healthy Volunteers
Food Effect on Pharmacokinetic Parameters of ABX464
The goal of this study is to determine the impact of the food on the absorption of the ABX464.
- Trial name
- NCT02731885
- Testing
- ABX464 Single dose, ABX464 Repeated dose
- Where
- Mauritius
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Abivax S.A.
Diabetic Nephropathy, Diabetic Kidney Disease
Pyridorin in Diabetic Nephropathy
The purpose of this study is to evaluate the safety and efficacy of oral Pyridorin 300 mg BID in reducing the rate of progression of nephropathy due to type 2 diabetes mellitus.
- Trial name
- PIONEER (NCT02156843)
- Testing
- Pyridorin
- Where
- 137 sites in United States, Australia and 10 more
- Volunteers
- 328 people
- Sponsor
- NephroGenex, Inc.
Hepatitis C, Chronic
A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C Patients
PPI-383 is an antiviral agent (an inhibitor of the hepatitis C virus NS5B polymerase) that is being developed as a potential treatment for hepatitis C virus infection.
- Trial name
- NCT01928147
- Testing
- PPI-383
- Where
- 6 sites in Mauritius, United Kingdom
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Presidio Pharmaceuticals, Inc.